An observational study in Cardiomyopathies, Genetic Predisposition and Cardiomyopathy, Primary, sponsored by NHS Greater Glasgow and Clyde. Recruiting at 1 site in United Kingdom. Open to participants aged 10 Years and older. Per ClinicalTrials.gov, last updated 2024-07-03.
Sponsored by NHS Greater Glasgow and Clyde · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 51 studies in Cardiomyopathies with a site in United Kingdom — 19 open to participants now, 24 under way, 5 of them phase 3. Cardiomyopathies · United Kingdom.
Among the 51 studies in Cardiomyopathies with a site in United Kingdom, this one is the 10th largest by planned enrollment of the 25 observational ones that give a count, is one of 3 that started in 2024, is one of 25 observational ones, reaches primary completion later than 8 of the 23 other live ones, and was the 43rd registered.
556 studies on the registry are indexed under Cardiomyopathies; 153 are open to participants now.
Browse Cardiomyopathies studies →19 of the 51 studies in Cardiomyopathies with a site in United Kingdom are open now. Recruiting first, the newest first:
Lexeo Therapeutics · Sites in United Kingdom, United States, Brazil and 6 more countries
Ages 6+
University of Manchester · Sites in United Kingdom
Ages 18+
Barts & The London NHS Trust · Sites in United Kingdom
Ages 18+
Bayer · Sites in United Kingdom, Austria, Belgium and 14 more countries
Ages 18+
Alnylam Pharmaceuticals · Sites in United Kingdom, United States, Argentina and 33 more countries
Ages 18–85
A study can be open while its sites in United Kingdom have not opened yet or have stopped. Only those recruiting at a site in United Kingdom →
Of the 116 Cardiomyopathies studies recruiting now, 70 (60%) set no upper age limit and 18 (16%) stop at 75 or younger; 35 take children under 18; 22 take healthy volunteers.
This study: 10 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
51 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 6 · Phase 3 12 · Phase 4 2
First in 2000; this study’s year is marked. 3 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 750 is above the median of 200 across 264 observational studies indexed under Cardiomyopathies.
Median enrollment 137 across the 26 interventional studies, 267 across the 25 observational. Of the 22 that completed or were terminated, 7 (32%) have results posted.
This tab as a report to print or save as PDF → With an account.
27 of 51 have an industry lead sponsor. The 10 most frequent:
NHS Greater Glasgow and Clyde is the lead sponsor of 220 studies on the registry; 38 are open to participants now.
NHS Greater Glasgow and Clyde has 2 studies filed under Cardiomyopathies — fewer than ten, so there is no comparison to draw.
7 of the studies in Cardiomyopathies with a site in United Kingdom that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04520347University of California, Los AngelesIVTCC 2.0: A Prospective Multicenter Ventricular Tachycardia Catheter Ablation Registry | 2026-12 |
| NCT03049254Mayo ClinicMayo AVC Registry and Biobank | 2027-03 |
| NCT06446271NHS Greater Glasgow and ClydeBiomarkers in SCOTland CardiomyopatHy Registry (Bio-SCOTCH) | 2027-03-19 |
| NCT07574697Barts & The London NHS TrustAIC Genotyping Study | 2027-03-31 |
| NCT07852221Insel Gruppe AG, University Hospital BernPatient Selection and Long-Term Outcomes of Pace & Ablate Strategy in Atrial Fibrillation | 2027-06-30 |
Add all 7 to your calendar (.ics) → With an account.
Among the 51 studies in Cardiomyopathies with a site in United Kingdom, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Genetic cardiomyopathy is increasingly recognised and can lead to heart failure, arrhythmia and sudden cardiac death. Some gene positive patients have rapidly progressive disease with high rates of heart failure and cardiac transplantation, while others present with SCD. Other gene positive patients will never develop cardiomyopathy. At present, we cannot distinguish between these groups and rely on expensive and labour-intensive surveillance by electrocardiography, echocardiography and sometimes cardiac magnetic resonance imaging.
This study will investigate existing and novel biomarkers (including blood, urine electrocardiographic and imaging) at various stages of disease in patients with a personal or family history of TTN, MYBPC3, LMNA, FLNC or DSP gene variant, which are known to cause cardiomyopathy.
There is a growing appreciation for the role that genetics play in the development of cardiomyopathy, which can lead to heart failure, arrhythmia and sudden cardiac death.
Increased use of genetic testing has identified numerous gene variants, which cause cardiomyopathy with dilated, hypertrophic, restrictive, non-dilated left ventricular and arrhythmogenic right ventricular phenotypes described.
Some gene variants cause a rapidly progressive cardiomyopathy with high rates of heart failure and cardiac transplantation, while others present with SCD, meaning that genotype-specific risk stratification and clinical surveillance is urgently needed. Some gene-positive individuals will never develop cardiomyopathy due to variable penetrance. At present, we cannot distinguish between these patients and therefore rely on expensive and labour-intensive surveillance by electrocardiography, echocardiography and sometimes cardiac magnetic resonance imaging. For every gene-positive affected individual with cardiomyopathy, cascade genetic testing will identify other gene-positive family members who are often asymptomatic and may not yet be affected.
A blood or urine-based biomarker that identifies pre-clinical disease or cardiomyopathy would allow for more efficient monitoring of gene positive people and could replace multiple, repeated electrocardiograms, echocardiograms and cardiac magnetic resonance imaging scans. A biomarker that accurately identifies pre-clinical cardiomyopathy could enable targeted early treatment. A biomarker that predicts future disease progression would be of high clinical value.
People with a personal or family history of TTN, LMNA, MYBPC3, DSP, or FLNC gene variant who have been referred to the West of Scotland Inherited Cardiac Conditions Service clinic.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Pathogenic and likely pathogenic variants defined by American College of Medical Genetics guidelines. Expected recruitment of: 300 TTN, 300 MYBPC3, up to 50 LMNA, up to 50 FLNC and up to 50 DSP
Diagnostic Test: Plasma biomarker levels
Expected recruitment of 50 patients.
Diagnostic Test: Plasma biomarker levels
This study will investigate existing and novel biomarkers (including blood, urine electrocardiographic and imaging) at various stages of disease in patients with a personal or family history of TTN, MYBPC3, LMNA, FLNC or DSP gene variant, which are known to cause cardiomyopathy. Cardiomyopathy will be defined per European Society of Cardiology cardiomyopathy guidelines and heart failure stage will be defined per American Heart Associate guidelines.
Also known as: Electrocardiogram, Echocardiogram, Cardiac magnetic resonance imaging, 24-hour Holter monitor, Questionnaires (Kansas City Cardiomyopathy Questionnaire & General Practice Physical Activity Questionnaire), Urine biomarker levels
Biomarker performance
Diagnostic performance of existing and novel biomarkers across the spectrum of disease in patients with pathogenic/ likely pathogenic TTN, MYBPC3, LMNA, FLNC or DSP gene variants.
Time frame: 3 years
Biomarker correlation
Correlation of biomarkers with cardiac imaging measures of inflammation and myocardial fibrosis in genetic cardiomyopathies.
Time frame: 3 years
Prediction of cardiomyopathy development
Investigation of biomarkers that can predict which patients (who are gene positive without cardiomyopathy) will develop cardiomyopathy, heart failure, arrhythmia, or die
Time frame: 3 years with long-term data linkage
Prediction of cardiomyopathy progression
Investigation of biomarkers that can predict which patients (who are gene positive with cardiomyopathy) will have progressive cardiomyopathy, heart failure, arrhythmia, or die.
Time frame: 3 years with long-term data linkage
Natural history of genetic cardiomyopathies
Investigate the natural history of genetic cardiomyopathy due to variants in TTN, MYBPC3, LMNA, FLNC and DSP genes.
Time frame: 3 years with long-term data linkage
Plan to share: No
No publications or documents are linked to this record.
Started Jun 2024 (actual). Primary completion is estimated for Mar 2027, 32 months after the start.
Of 119 non-industry observational studies under Cardiomyopathies, half reached primary completion within 87 months of starting (the median), counting those still running; a quarter within 34. This study's planned 32 months is below that.
Counting every sponsor, half of 141 studies reached it within 83 months; a quarter within 34.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
NHS Greater Glasgow and Clyde →